Drugs / MART-1 antigen
MART-1 antigen
Trials 23 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00091338 Background | Aug 2004 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00025181 Background | Oct 2001 → Jan 2003 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1 antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00303836 ↗ |
| Known as | HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01082198 ↗ |
| Known as | MART-1 | “The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 2003 |
| Known as | MART-1a | “melanoma-associated peptide (MART-1a)” PMID 32752904 ↗ Aug 2020 |
| Action | Deplete | “Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗ |
| Modality | Vaccine | “melanoma peptide vaccine comprising tyrosinase:368-376 peptide, gp100:209-217 antigen, and MART-1:26-35 antigen emulsified in Montanide ISA-51” NCT00005841 ↗ |
| Route | Subcutaneous | “Patients receive melanoma peptide vaccine comprising tyrosinase:368-376 peptide, gp100:209-217 antigen, and MART-1:26-35 antigen emulsified in Montanide ISA-51 subcutaneously...” NCT00005841 ↗ |